Somewhere in the sun-scorched deserts of the American Southwest, a slow-moving, beaded lizard holds the unlikely origin story of one of the most transformative medical breakthroughs of our lifetime. The Gila monster can go months without eating — its body working quietly, efficiently, without distress. Scientists got curious. What they eventually found in its saliva was a hormone strikingly similar to one made in the human gut. That discovery would lead to drugs now generating over $53 billion in annual global sales, reshape Hollywood body culture, ignite fierce ethical debates, and fundamentally change how medicine understands hunger, weight, and metabolic disease.
Welcome to the world of GLP-1s.
What Exactly Is a GLP-1?
GLP-1 stands for Glucagon-Like Peptide-1 — a hormone your own body has been producing your entire life. Specialized cells lining your small intestine release it after every meal, especially in response to fiber, protein, and certain fats. In a healthy system, GLP-1 simultaneously triggers insulin release from the pancreas, tells the brain you have had enough to eat, slows how quickly the stomach empties, and blocks a counter-hormone called glucagon from raising blood sugar further.
Think of it as your body’s elegant, multi-organ “I’ve had enough” message. The problem is that in many people with obesity or type 2 diabetes, this signal becomes blunted. The message is weaker, slower, harder for the body to hear. And the hunger keeps coming — not because of weak willpower, but because of disrupted biology.
The Exhaustion That Drove Millions to Finally Ask for Help
Let’s say something honest that millions of people have felt for decades but rarely heard validated: “eat less and move more” has not worked for them. Not because they didn’t try. Not because they didn’t care. But because that advice — repeated endlessly by doctors, magazines, and well-meaning strangers — never accounted for the deeply biological nature of how hunger, appetite regulation, and weight actually work.
Obesity is not a character flaw. It is a chronic, biologically driven disease shaped by genetics, hormones, the gut microbiome, inflammation, stress, sleep, and environment. For people whose GLP-1 signaling is disrupted, no amount of determination fully compensates for a system that is wired — at the cellular level — to hold onto weight and keep searching for food. Many describe it as a relentless mental noise around eating, a hunger that never fully quiets no matter how disciplined they are.
This is the exhaustion — bone-deep, years-long — that has driven millions of people to GLP-1 medications. Not laziness. Not vanity. The specific fatigue of fighting your own biology with inadequate tools, and the hope that something might finally work.
“For so many decades, we told everyone the problem was you — eat less, move more. GLP-1 receptor agonists have allowed us to truly understand that biology is far more powerful than that.” — Dr. Jennifer Manne-Goehler, Mass General Brigham
From Gila Monster to Global Blockbuster
In the 1970s, scientists identified incretin hormones — GLP-1 and GIP — as post-meal signals that powerfully boosted insulin. The clinical leap came when researchers found that exendin-4, a compound in Gila monster saliva, mimicked human GLP-1 but remained stable in the bloodstream long enough to be medically useful. The first GLP-1 drug, exenatide (Byetta), received FDA approval in 2005 for type 2 diabetes. Then came liraglutide, then the molecule that changed everything: semaglutide — the active ingredient behind Ozempic, Wegovy, and Rybelsus. Clinical trials demonstrated 15–24% total body weight loss, results previously only seen after bariatric surgery. The GLP-1 era had arrived.
The Drug Lineup: What’s Available in 2025–2026
- Ozempic (semaglutide) — weekly injection, approved for type 2 diabetes, widely used off-label for weight management.
- Wegovy (semaglutide) — higher-dose version approved specifically for chronic obesity management.
- Mounjaro (tirzepatide) — dual GLP-1/GIP receptor agonist for type 2 diabetes; GIP amplifies GLP-1’s effects and also improves how fat cells respond to insulin.
- Zepbound (tirzepatide) — obesity-approved version; clinical trials showed average weight loss up to 22.5%.
- Oral Wegovy — pill form of semaglutide approved for weight loss in early 2025 — a milestone for needle-averse patients.
- Orforglipron (Foundayo) — first fully oral, non-peptide, daily GLP-1 agonist, FDA-approved 2026.
In 2024, Wegovy became the first weight-loss drug also approved to reduce serious cardiovascular events. Tirzepatide gained approval for obesity-related sleep apnea. In September 2025, the WHO added GLP-1 therapies to its Essential Medicines List — a signal that these are no longer specialist drugs but global health infrastructure.
By the Numbers: A Truly Global Phenomenon
New Zealand approved Wegovy for weight loss in March 2025, with early data from Health New Zealand showing over 18,000 people prescribed the drug in its first three months. In Great Britain, GLP-1 use nearly doubled in a single year — rising from 2.3% of adults in March 2024 to 4.1% by early 2025, per UCL research. In Australia, sales increased almost ten-fold between May 2020 and April 2025, with nearly half of all use occurring through the private market at $200–$600 per month. Globally, over one in four adults worldwide is estimated to be eligible for GLP-1 therapy for weight management.
How GLP-1 Drugs Work — A Plain-Language Guide
GLP-1 receptor agonists are long-lasting synthetic versions of your body’s own GLP-1 hormone. Naturally occurring GLP-1 breaks down in about two minutes; pharmaceutical versions are engineered to remain active for hours to a full week. Here is what they do across multiple organ systems:
In the Pancreas
They trigger insulin release only when blood glucose is elevated — a “glucose-dependent” mechanism that is far safer than older diabetes drugs, which could cause dangerous blood sugar crashes in people without diabetes.
In the Brain
GLP-1 receptors are distributed throughout the hypothalamus, which controls hunger and reward. Many users describe what finally happens as “the food noise stopping” — the relentless mental preoccupation with eating that people without metabolic disruption rarely experience. Cravings quiet. Smaller portions feel satisfying.
In the Heart and Kidneys
Major cardiovascular trials show GLP-1 drugs reduce systemic inflammation and lower the risk of heart attacks and strokes by approximately 14–20% in high-risk populations. Semaglutide (Ozempic) also now carries an indication for diabetic kidney disease — directly protecting kidney tissue by reducing inflammation within kidney vessels and improving blood flow, slowing a condition that is the leading cause of kidney failure worldwide.
In the Gut
GLP-1 medications significantly slow gastric emptying — how quickly food leaves the stomach — which is why users feel full on much smaller amounts. This same mechanism is responsible for the most common side effects, and it is also deeply connected to why gut health matters so profoundly in this conversation. We explore that in full in Part Four — but first, there are things your prescription almost certainly did not tell you.
The Bottom Line
GLP-1 medications work on multiple organ systems at once — not just appetite. Pairing them with supportive nutrition and lifestyle changes to address root causes may help improve long-term results and reduce the risk of weight regain after treatment.
These drugs are genuinely remarkable. But they are not the whole story. In Part Two, we pull back the curtain on what most people are never told before they start: the full range of side effects, how GLP-1s actually compare to bariatric surgery, and the uncomfortable truth about what happens to your body — and your hard-won results — when the medication stops. If you are considering these drugs, already taking them, or supporting someone who is, this is the part you need to read.
Not sure where to start? Book a free discovery call — let’s talk about what your body actually needs.
References
Bloomgarden Z. An update on GLP-1 receptor agonists. J Diabetes. 2025. doi:10.1111/1753-0407.70147
GLP-1 receptor agonists beyond diabetes management. EClinicalMedicine. 2024;79:103021. doi:10.1016/j.eclinm.2024.103021
Centers for Disease Control and Prevention. GLP-1 injectable use among adults with diagnosed diabetes. NCHS Data Brief. 2025;537. Accessed May 4, 2026. https://www.cdc.gov/nchs/products/databriefs/db537.htm
JPMorgan. How supply and demand for weight loss drugs is playing out in 2026. February 2026. Accessed May 4, 2026. https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
CBC News. 3 million Canadians use GLP-1 drugs. March 4, 2026. Accessed May 4, 2026. https://www.cbc.ca/news/health/canadians-glp1-ozempic-mounjaro-9.7114197
Pan XH, et al. The GLP-1 RA boom: trends in Australia 2020–2025. medRxiv. 2025. doi:10.1101/2025.10.30.25339120
UCL News. 1.6 million UK adults used weight loss drugs in past year. January 2026. Accessed May 4, 2026. https://www.ucl.ac.uk/news/2026/jan/16-million-uk-adults-used-weight-loss-drugs-past-year
RaboResearch. Every bite counts — GLP-1 medicines and the future of food. November 2025. Accessed May 4, 2026. https://www.rabobank.co.nz/media-releases/2025
RAND Corporation. Nearly 12 percent of Americans have used GLP-1 weight loss drugs. August 2025. Accessed May 4, 2026. https://www.rand.org/news/press/2025/08
World Health Organization. WHO issues global guideline on GLP-1 medicines. December 2025. Accessed May 4, 2026. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline
Berk KA, et al. More than a quarter of adults worldwide could benefit from GLP-1 medications. Lancet Diabetes Endocrinol. 2026. doi:10.1016/S2213-8587(25)00340-X